France· FR:66728045
KOSELUGO 25 mg, gélule
A selumetinib product containing hydrogénosulfate de sélumétinib, registered in France by ASTRAZENECA AB, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Selumetinib is registered in 16 of 19 countries.
Countries holding a registration under ATC L01EE04 (selumetinib), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 10 of them publish a price we can compare per daily dose
Selumetinib · ATC L01EE04
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of selumetinib costs, country by country.
Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Selumetinib · price per daily dose (50 mg)
USD · FX 28 Sept 2026
- CH Switzerland$482.52
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- HYDROGÉNOSULFATE DE SÉLUMÉTINIB
- Manufacturer
- ASTRAZENECA AB
- Country
- France (FR)
- ATC code
- L01EE04
- ATC class
- Selumetinib
- Defined daily dose
- 50 mg, O
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- cip1334009302301831 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 60 gélule(s)EUR 11.54
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
111 interactions on record for selumetinib.
Graded by severity as the source publishes them — 30 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Selumetinib · interactions on record
111 records
- 30 severe
- 81 moderate
Most severe, free to view
- AprepitantA04AD12severe
- DexamethasoneH02AB02severe
- KetoconazoleH02CA03severe
- ChloramphenicolJ01BA01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Selumetinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandKoselugoOrifarm Oy
- CanadaKOSELUGOALEXION PHARMA GMBH
- SwitzerlandKoselugo
- CzechiaKOSELUGOAstraZeneca AB, Södertälje
- SpainKOSELUGO 25 mg CAPSULAS DURASAstrazeneca Ab
- United KingdomKoselugo 25mg capsulesAstraZeneca UK Ltd
- IrelandKoselugo 25 mg hard capsulesAstraZeneca AB
- IcelandKoselugoAstraZeneca AB*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Koselugo
- Liechtenstein · Koselugo
- Norway · Koselugo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8629671c-7979-4593-a702-9fac763c2dbf GET /v1/drugs/8629671c-7979-4593-a702-9fac763c2dbf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66728045",
"date_amm": "2021-06-17",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1552",
"substance": "HYDROGÉNOSULFATE DE SÉLUMÉTINIB",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "gélule",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about selumetinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.